FHTX Q2 2022 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$322M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+1509.3% YoY

Gross Profit

-$21M-478.5% margin

Operating Income

-$29M-650.1% margin

Net Income

-$27M-608.3% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

+14.5%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$457M

Total Liabilities

$409M

Stockholders' Equity

$48M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$279,000	+1509.3%
Gross Profit	-$21M	-$18M	-17.0%
Operating Income	-$29M	-$23M	-25.5%
Net Income	-$27M	-$23M	-18.2%